Skip to main content
Clinical Trials/NCT04895631
NCT04895631
Recruiting
Phase 3

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

Thomas Hope1 site in 1 country140 target enrollmentJune 30, 2021

Overview

Phase
Phase 3
Intervention
18F-Fluorocholine
Conditions
Hyperparathyroidism, Primary
Sponsor
Thomas Hope
Enrollment
140
Locations
1
Primary Endpoint
Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using sestamibi imaging
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.

Detailed Description

PRIMARY OBJECTIVE: I. To investigate the performance (accuracy) of 18F-fluorocholine PET in the detection of hyperfunctioning parathyroid glands in surgical patients with biochemically proven primary hyperparathyroidism. OUTLINE: Participants will receive a single dose of 18F-Fluorocholine at the time the participant undergoes a single imaging study using 18F-fluorocholine. Study related procedures will end after the study visit. Participants who undergo subsequent parathyroidectomy, will have the results reviewed and compared to the results from the imaging study

Registry
clinicaltrials.gov
Start Date
June 30, 2021
End Date
June 30, 2027
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Thomas Hope

Associate Professor

University of California, San Francisco

Eligibility Criteria

Inclusion Criteria

  • Age \>= 13 years.
  • Biochemically proven hyperparathyroidism and an indication for surgery.
  • Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria

  • Current Pregnancy.
  • Patients unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.

Arms & Interventions

Fluorocholine PET Imaging

Patients will undergo a single fluorocholine PET imaging study prior to surgery.

Intervention: 18F-Fluorocholine

Fluorocholine PET Imaging

Patients will undergo a single fluorocholine PET imaging study prior to surgery.

Intervention: Positron emission tomography (PET)

Outcomes

Primary Outcomes

Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using sestamibi imaging

Time Frame: Up to 1 year

Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.

Proportion of participants with true-positives (sensitivity) of 18F-Fluorocholine PET using predefined threshold

Time Frame: Up to 1 year

Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology compared to a predefined threshold. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.

Secondary Outcomes

  • Detection rate of 18F-fluorocholine PET(Up to 1 year)

Study Sites (1)

Loading locations...

Similar Trials

Enrolling By Invitation
Phase 3
Fluorocholine PET/CT Basket TrialFluorocholine PET/CT
NCT04150458Sir Mortimer B. Davis - Jewish General Hospital2,000
Withdrawn
Early Phase 1
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue SarcomaStage II Adult Soft Tissue SarcomaStage IIA Adult Soft Tissue SarcomaStage IIB Adult Soft Tissue SarcomaStage IIC Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
NCT03613259OHSU Knight Cancer Institute
Active, not recruiting
Early Phase 1
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical CystectomyBladder CancerUrothelial Carcinoma
NCT04018053Brigham and Women's Hospital16
Completed
Early Phase 1
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing SarcomaAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Ewing Sarcoma of BoneExtraosseous Ewing SarcomaLocalized Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorUntreated Childhood Supratentorial Primitive Neuroectodermal Tumor
NCT01825902Mayo Clinic1
Completed
Phase 2
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone MetastasesHormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneRecurrent Prostate CarcinomaStage IV Prostate Cancer
NCT00936975National Cancer Institute (NCI)18